

Protein Characterization and Biosafety Testing Services Simplifying Progress

SARTURIUS



The 4Cell® CHO Platform: Integrated Service Package From DNA to Cell Banks

DNA to Cell Banks

Predictable performance and accelerated drug development with our integrated CHO platform

Cell Line Development

RCB and Basic Analysis

Services

- Stable, ready to scale clones
- From DNA to RCB in 9 weeks
- Predictable protein titers: up to 10 g/L

Protein Characterization

Advanced Molecule Analysis

- Product Quality Assessments
- Assay development expertise
- Full assay lifecycle management

Cell Banking

Frozen MCB Vials

- GMP Master & Working cell banks
- 500 vial @ 12 mio. cells/vial
- Qualified Person for cell bank release

Biosafety testing

GMP Qualified MCB | WCB

- Validated GMP Release Assays
- Sterility, Mycoplasma, Virus Testing
- Genetic Characterization

4Cell® SmartCHO Media



Excellent Customer Service

A dedicated team of Client Managers provides a single point of contact to the client throughout the Cell Line Development (CLD) process, from DNA to released Master Cell Bank (MCB) | Working Cell Bank (WCB), as well as the transfer to the CMO of the client's choice. Our Client Managers facilitate the flow of information, so you can reach IND faster.

- Over 80% of customers return to Sartorius for their next CLD project
- One point of contact with regular updates on your project
- Expert technical assistance and guidance throughout early-stage development to lot release



Leading Service Provider

The foundation for approval of new biological entities is built on a robust analytical data package that proves the safety, purity and potency of the product. The Sartorius analytical testing package combines physicochemical and biological analysis for in-depth characterization studies from a single contract partner. Our service offering uses platform methods, off-the-shelf assays and custom developed bioassays to enable rapid data-driven decisions during drug development and is available from pre-clinical through to clinical phases and lot release. Coupled with our extensive options as part of the 4Cell® CHO platform including cell line development, biosafety testing, and cell bank manufacturing, Sartorius is the preferred choice for your program.

Technical Expertise

"Over the 3 years working with Sartorius, the team has been knowledgeable, engaged, and proactive. They consistently and professionally deliver on promise with no surprises. A truly pleasant experience."

Client Quote

- >15 years' experience
- 99% delivery on time
- Highly experienced & knowledgeable scientists
- Experts in development, optimization & validation of complex cell-based potency bioassays & binding assays
- Full range of off-the-shelf assays for routine characterization of monoclonal antibodies
- Dedicated team of protein characterization experts



Our Services

We have extensive expert knowledge to support your New Biological Entity (NBE) or Biosimilar with our off-the-shelf and custom assays, as well as regulatory compliant biosafety testing in the following areas:

- Bioassays
- Cell-based Potency Assays
- Binding Assays
- Physicochemical & Structural Analyses
- Qualification & Validation

Our Approach = Your Success

Speed Faster assay development to shorten your

timeline to IND submission

Flexibility Tailored testing packages

Expertise Extensive experience & full range of

platform methodologies

Compliant Fully current Good Manufacturing Practice

(cGMP) compliant laboratories

Integrated Full service package available

Development Services

Customizable Off-the-Shelf

Qualification

Validation

Our method lifecycle approach takes you from pre-clinical development through to phase III validation and commercial lot release, with a smooth transition to cGMP services from our fully compliant laboratories.

Early Assay Development & Screening

- Custom Assay Development Design of Experiments (DoE)
- Tech Transfer
- Optimization (DoE)



Structural and Physiochemical Analytical Package

- Supporting your development process from pool | clone selection
- Assessments of product stability
- Methods to meet regulatory standards



Analytical Methods Qualification

- ICH Q6B Specifications:
 Test Procedures and Acceptance
 Criteria for Biotechnological |
 Biological Products
- ICH Q2B Validation of Analytical Procedures

Protein Characterization Testing Services


Our panel of off-the-shelf monoclonal antibody characterization assays are ready to go for a range of targets (TNF, CD20, VEGF, HER2, EGFR, PD-1, PD-L1, IgE, IL-12/23, RANKL. etc).

Our assays have been qualified with commercially available innovator mAbs such as Humira, Rituxan, Herceptin, Avastin etc.

Sartorius with clients throughout the molecule development pathway:



Our highly experienced team of scientists have developed methods for molecule characterization in line with regulatory requirements, allowing comprehensive analysis of NBE molecules and comparability of biosimilars to the originator molecule.



Full Range of Fc Effector Binding & Functional Assays

- Protein therapeutics: Characterization of immunological and biological properties
- Experience in Fc characterization assays including binding to C1g, Fc receptors, ADCC & CDC

cGMP Method Validation

- Product specific validation supporting stability studies & lot release
- USP1033, Ph. Eur. & ICH Q2B specifications

Biosimilars Testing

Industry Leader

Characterization and comparability of biosimilar monoclonal antibodies

Expertise

Industry leading experience working with over 15 biosimilar molecules and 30+ biosimilar developers

Speed to Market

Comprehensive range of off-the-shelf assays for biosimilar characterization and comparability to ensure cost effective results

Greater Quality Assurance

Excellent regulatory and industry insight for generating data required for regulatory submissions

Experience

Sartorius offer a variety of methods to support the testing of a wide range of biosimilar monoclonal antibodies including:

- Herceptin (trastuzumab)
- Humira (adalimumab)
- Enbrel (etanercept)
- Avastin (bevacizumab)
- Lucentis (ranibizumab)
- Rituxan (rituximab)
- Remicade (infliximab)
- Stelara (ustekinumab)

- Simponi (golimumab)
- Prolia (denosumab)
- Actemra (tocilizumab)
- Synagis (palivizumab)
- Eylea | Zaltrap (aflibercept)
- Xolair (omalizumab)
- Orencia (abatacept)
- Yervoy (ipilimumab)

Currently, in our R&D pipeline we are developing methods to support assessments of biosimilarity for the following molecules:

- Erbitux (cetuximab) target EGFR
- Opdivo (nivolumab) target PD-1
- Imfinzi (durvalumab) target PD-L1
- Tecentriq (atezolizumab) target PD-L1
- Keytruda (pembrolizumab) Target PD-1



Packages for Testing Services


Utilising decades of experience in testing services, we are now offering pre-determined packages for all of your testing needs. These cover full characterization of your molecule, generation of master and working cell banks, and all required biosafety testing. All packages have been carefully assembled with our recommended assays in order to satisfy all regulatory requirements, and accelerate the speed at which your molecule reaches the clinic.

Please speak with us to discuss these packages further, and understand how Sartorius can help you to simplify progress.

Protein Characterization

- Complete protein characterization package of recommended assays for your molecule
- Streamlines processes and accelerates the development of your molecule to the clinic; packages contain sample testing and all method development | feasibility
- Packages are available for protein characterization at either top 4 clone, or lead clone stage

Recommended Protein Characterization Packages



	Top 4 Clones	Lead Clone
Standard IgG		
Standard* package	✓	✓
Extended package	✓	✓
Appended IgG		
Standard* package	✓	✓
Extended package	✓	✓

^{*}The standard package provides the minimum recommended level of testing for protein characterization, whilst the extended package provides a greater number of assays for additional protein characterization work.

For further information on these packages, visit sartorius.com/en/services/biologics-testing




Integrated Biosafety Testing Services

As part of our integrated service offering for a complete solution, we also offer comprehensive biosafety testing services, including cell bank characterization and genetic stability assessments of the final producer cell lines to assess the safety of biologics throughout the drug development pathway.

Our scientists have a wealth of knowledge and experience in biosafety testing, coupled with a thorough understanding of the regulatory requirements for the release of cell banks, molecules, and the cell lines used to manufacture these products.

Biosafety Testing

- Packages available for:
 - Master Cell Bank Biosafety
 - Working Cell Bank Biosafety
 - End of Production Cell Bank Biosafety
- Contain all necessary assays to satisfy regulatory requirements for biosafety testing and release of cell banks.
- One single price for all of your biosafety testing requirements.



Global Facilities of Sartorius for Cell Line Development, Cell Bank Manufacturing and Testing Services



Germany

Sartorius Stedim Biotech GmbH August-Spindler-Strasse 11 37079 Goettingen Phone +49 551 308 0

Sartorius Stedim Cellca GmbH Marie-Goeppert-Mayer-Str. 9 89081 Ulm-Eselsberg Phone +49 731 206520



Ror more information, visit

sartorius.com

USA

Sartorius Stedim North America Inc. 565 Johnson Avenue Bohemia, NY 11716 Toll-Free +1 800 368 7178

UK

Sartorius Stedim BioOutsource Ltd. 1 Technology Terrace, Todd Campus, West of Scotland Science Park Glasgow, G20 0XA, Toll-Free +44 141 946 4222